Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
复制标题
免疫检查点治疗和预测生物标志物的搜索。
DOI：
10.1097/ppo.0000000000000185
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Sharma,Padmanee
中科院分区：
文献类型：
--
作者：
Sharma,Padmanee
免疫检查点疗法在肿瘤学领域引发了一场革命。免疫系统在抗肿瘤反应中起着关键作用的概念已经存在了几十年，最终得到了证实，并通过优雅的临床前研究和由于阻断抑制性T细胞途径的抗体而在患者中产生的戏剧性临床反应而牢固确立。然而，临床反应仅在一部分患者中实现，需要更多的工作来更好地了解引起肿瘤排斥的机制，这将能够识别适当的生物标志物，揭示新的靶点，提供指导联合研究的数据，并最终决定一个平台，允许更多的患者通过免疫检查点疗法获得临床益处，包括治愈。
Immune checkpoint therapy has started a revolution in the field of oncology. The concept that the immune system plays a critical role in antitumor responses, which has been around for decades, has finally been proven and firmly established with elegant preclinical studies and dramatic clinical responses in patients as a result of antibodies that block inhibitory T-cell pathways. However, the clinical responses being achieved are only in a subset of patients, and more work is needed to provide a better understanding of the mechanisms that elicit tumor rejection, which will enable identification of appropriate biomarkers, reveal new targets, provide data to guide combination studies, and eventually dictate a platform that allows more patients to derive clinical benefit, including cures, with immune checkpoint therapy.